You may be asked if you would like to take part in a clinical trial in order to test a new drug or to donate some blood or a tissue sample which may help in our understanding of melanoma.
If you are on a drug trial a research nurse will co- ordinate your care and treatment schedule, and will be a good source of advice about the trial. You will be introduced to the research nurse when you consent to be in a trial.
This page is updated monthly with information about current open melanoma trials at The Christie. Full details about these active trials with information about eligibility, inclusion and exclusion criteria can be found via Useful Links on the CRUK and National Cancer Institute websites. There is also a 15 minute YouTube film about taking part in clinical trials (this is general and not specific to melanoma trials.) For the link to the video go via Useful Links.
Current open trials - updated 02/05/18
IMspire 170 A phase III, open-label, multicenter, two-arm, randomised study to investigate the efficacy and safety of Cobimetinib plus Atezolizumab versus Pembrolizumab in patients with previously untreated advanced Brafv600 wild-type melanoma.
BMS CA224-020 A phase 1/2a dose escalation and cohort expansion study of the safety, tolerability, and efficacy of Anti-LAG-3 monoclonal antibody (BMS-986016) administered alone and in combination with Anti-PD-1 monoclonal antibody (Nivolumab, BMS-936558) in advanced solid tumours.
INTERIM A randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy in patients with BRAFV600 mutant stage 3 unresectable or metastatic melanoma.
Nektar PIVOT A Phase 1/2, open-label, multicentre, dose escalation and dose expansion study of NKTR-214 and Nivolumab in patients with select locally advanced or metastatic solid tumour malignancies
Immunocore IMCgp100-201 A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
PIANO PLX3397 KIT in Acral and Mucosal Melanoma (trial currently on hold) To evaluate the efficacy and safety of PLX3397 in the treatment of advance form of KIT mutated melanoma.
SelPac A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma
Recruitment now closed to the following trials:
Combi-i A randomised, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma.
PERM (16_DOG12_87) A randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma
BMS CA017-055A Phase 3, randomized, double-blind study of BMS-986205 combined with Nivolumab versus Nivolumab in participants with metastatic or unresectable melanoma that is previously untreated.
Checkmate 915 (17_DOG12_96) A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
PACMEL A trial looking at GSK1120212 and pazopanib with paclitaxel for people with melanoma.
MelMarT A surgical pilot study, initially recruiting until December 2015. A Phase III, multi-centre, multinational randomised control trial investigating 1cm v 2 cm wide excision margins for primary cutaneous melanoma.
Checkmate 401 Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma.
MASTERKEY-265 A Phase 1b/3, Multicentre, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma.
EORTC 18081 Adjuvant peginterferon alfa-2b for 2 years vs Observation in patients with an ulcerated primary cutaneous melanoma with T(2-4)bN0M0: a randomized phase III trial of the EORTC Melanoma Group.
MK3475-252 (Keynote 252) A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) Read more about this via the link.
Checkmate 511 Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination with Ipilimumab 1 mg/kg vs Nivolumab 1mg/kg in Combination with Ipilimumab 3 mg/kg in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma
MILLENNIUM An Open Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumours Followed by Dose Expansion Phase in Patients with Metastatic Melanoma.
KEYNOTE 054 (follow the link to read the latest) Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group
UKMCC-01 A Phase II Study of Pazopanib in Metastatic Merkel Cell Carcinoma
CHECKMATE 172 The trial is a Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA-4 Monoclonal Antibody.
Checkmate 238 (CA209-238) A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence.
COLUMBUS Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma.
Still recruiting but no longer to the vemurafenib arm, just to a combination of LGX818 Plus MEK162 arm and LGX818 Monotherapy arm)
SCANCELL A trial of SCIB1 injections for melanoma